IXICO has extended two existing contracts and they will contribute an additional £2.4m in revenues.
The neuroscience-focused data analytics company has secured a £1.8m extension to a phase III study in Huntingdon’s Disease and a £600,000 extension for a study in progressive supranuclear palsy.
The contracted order book was £15.9m at the end of September 2019. Other contracts have been added since then.
In the year to September, IXICO increased its revenues from £5.4m to £7.6m and it moved into profit for the first time. Pre-tax profit was £366,000.
There was £7.3m in the bank at the end of September 2019.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.